TAMs predominantly exhibit an M2 phenotype within the tumor microenvironment, characterized by the secretion of anti-inflammatory cytokines (e.g., IL-10, TGF-β), expression of immune checkpoint molecules, and promotion of regulatory T cell (Treg) recruitment. The gene discussed is TGFB1; the disease is neoplasm.